| 6/24/2024 | BKCVEMHY | S&P turns Teva outlook to positive
|
| 5/31/2023 | BKCVEMHY | S&P turns Teva outlook to stable
|
| 3/6/2023 | BKCVEMHY | S&P assigns BB- to Teva notes
|
| 3/1/2023 | BKCVEMGNHY | Fitch assigns BB- to Teva notes
|
| 2/27/2023 | BKCVDDEMIGPV | Market Commentary: Triumph, Teva on deck; Tegna tanks on FCC acquisition opposition; TransDigm, Uniti improve
|
| 7/29/2022 | BKCVEMGNHY | S&P lifts Teva outlook to positive
|
| 7/27/2022 | BKCVDDEMIGPV | Market Commentary: Avient prices; secondary surges post-Fed; cross-over credits in demand; Teva gains on settlement
|
| 12/15/2021 | BKCVEMGNHY | Moody's turns Teva outlook to stable
|
| 12/6/2021 | BKCVEMGNHY | Fitch revises Teva view to stable
|
| 11/4/2021 | BKCVDDEMIGPV | Market Commentary: DCP Midstream, Asbury Automotive price; Teva active; Continental gains; CommScope sinks
|
| 11/3/2021 | BKCVDDEMIGPV | Market Commentary: Junk secondary unmoved by Fed tapering statement; Teva flat; Jane Street on a 101-handle
|
| 11/1/2021 | BKCVDDEMIGPV | Market Commentary: Mr. Cooper, Navient price; loanDepot gains on earnings beat; PG&E active
|
| 9/3/2020 | CV | S&P trims Teva
|
| 9/3/2020 | BKCVEMHY | S&P trims Teva
|
| 11/18/2019 | BKCVDDEMIGPV | Market Commentary: iHeart, Boyd, Mattel, MSCI add-on price; Prestige Brands trades up
|
| 11/14/2019 | BKCVEM | Moody’s rates Teva notes Ba2
|
| 11/13/2019 | BKCVEM | S&P rates Teva notes BB
|
| 11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
| 11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
| 10/24/2019 | BKCVEM | S&P places Teva ratings on CreditWatch negative
|
| 10/21/2019 | BKCVDDEMIGPV | Market Commentary: United Rentals, KB Home price; newer notes trade; Teva lifted; Coty falls; WeWork higher
|
| 10/21/2019 | CV | Market Commentary: Snap convertibles little moved as shares jump; Workday notes active near recent lows
|
| 10/18/2019 | BKCVDDEMIGPV | Market Commentary: Neptune Energy adds; Evoca prices; Thursday issuance higher; Teva up; WeWork better
|
| 10/16/2019 | BKCVDDEMIGPV | Market Commentary: Merlin, Speedway price; new Charter notes rise; pharma names up; Sprint, T-Mobile higher
|
| 8/28/2019 | BKCVDDEMIGPV | Market Commentary: Pharma space under pressure; Rackspace higher; Tallgrass negative; oil names rise
|
| 8/27/2019 | BKCVDDEMIGPV | Market Commentary: Pharma names see negativity; Range Resources varies; GTT declines
|
| 8/14/2019 | BKCVEM | Moody’s revises Teva view to negative
|
| 8/13/2019 | BKCVDDEMIGPV | Market Commentary: Post Labor Day pipeline eyed; Tenet bounces off lows; Teva drops; Goodyear Tire rises
|
| 7/23/2019 | BKCVDDEMIGPV | Market Commentary: JBS USA, Five Point add-on price; Teva in focus; LSC Communications craters
|
| 7/5/2019 | BKCVDDEMIGPV | Market Commentary: Trading light; Altice USA backs off gains; Teva active but flat; funds add $800 million
|
| 6/7/2019 | BKCVEM | Fitch downgrades Teva
|
| 6/3/2019 | BKCVDDEMIGPV | Market Commentary: Multi-Color, Grubhub on tap; Neiman Marcus, GCI price; Teva in focus, gains; Altice up
|
| 6/3/2019 | CV | Market Commentary: New Mountain taps 5.75% notes; Cypress Semiconductor in focus; ON Semiconductors better
|
| 5/29/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial prices; Frontier gains; Teva’s downward spiral continues; CRC drops
|
| 5/28/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial, GoDaddy on tap; Fiat up on merger; Teva drops post settlement
|
| 5/15/2019 | BKCVDDEMIGPV | Market Commentary: Transocean prices; Berry on tap; VistaJet active; Teva, Commscope under pressure
|
| 5/13/2019 | BKCVDDEMIGPV | Market Commentary: Eldorado on tap; Bausch Health weakens; Charter below par; Weatherford, Teva down
|
| 2/15/2019 | BKCVEM | S&P revises Teva view to negative
|
| 2/14/2019 | BKCVEM | S&P lowers Teva view to negative
|
| 1/4/2019 | BKCVDDEMIGPV | Market Commentary: Risk-on sentiment returns; CDX sees largest single-day gain in four years; energy outperforms
|
| 1/3/2019 | BKCVDDEMIGPV | Market Commentary: No new deals in sight; trading volume light; Western Digital active; Qorvo drops; Teva up
|
| 11/1/2018 | BKBWCVEMHY | Israel’s Teva is using majority of cash flow to reduce leverage to 3x
|
| 10/11/2018 | BKCVDDEMIGPV | Market Commentary: Millicom prices; TransDigm rises on acquisition; energy mixed; Teva Pharaceutical improves
|
| 10/10/2018 | CV | Market Commentary: Convertibles calm as equities sell off; Granite Point prices; Karyopharm stock plunges
|
| 9/25/2018 | CV | Market Commentary: Convertibles market eyes CenterPoint Energy offering; Chesapeake Energy, Novavax active
|
| 9/25/2018 | CV | Market Commentary: Morning Commentary: Market eyes CenterPoint Energy offering; Chesapeake Energy active
|
| 8/15/2018 | BKCVEM | Fitch affirms Teva Pharmaceutical
|
| 7/27/2018 | BKCVDDEMIGPV | Market Commentary: Hi-Crush prices, euro primary active; Party City’s new issue lower; Teva slides
|
| 7/26/2018 | BKCVDDEMIGPV | Market Commentary: Party City prices; Teva improves; Aleris acquired; SuperValu bought; funds off $548 million
|
| 7/20/2018 | BKCVDDEMIGPV | Market Commentary: Comstock prices; Bruin carried over; secondary trading light; IHS Markit eyed; Teva active
|
| 7/9/2018 | CV | Market Commentary: Palo Alto Networks to sell $1.5 billion convertible; Teva active; Ironwood a concern
|
| 3/16/2018 | BKCVDDEMIGPV | Market Commentary: Tullow, Husky lead busy primary; Mattel trades on Toys shutdown; Teva still trades under par
|
| 3/7/2018 | BKCVDDEMIGPV | Market Commentary: Upsized Teva megadeal prices; new Ball notes busiest; CIT trades up; Frontier mostly up
|
| 3/6/2018 | BKCVDDEMIGPV | Market Commentary: Three-part CIT drive-by leads deal parade; Ball, William Lyons, Buena Vista also price
|
| 2/28/2018 | BKCVEM | S&P rates Teva notes BB
|
| 2/28/2018 | BKCVEM | Moody’s applies Ba2 to Teva notes
|
| 1/12/2018 | BKCVEM | Moody’s downgrades Teva to Ba2
|
| 12/15/2017 | CV | Market Commentary: Teva in focus, Bristow still going strong, adios to Intel
|
| 12/14/2017 | CV | Market Commentary: Bristow gains then eases a little, Teva better on restructuring; Cobalt bankruptcy no surprise
|
| 12/14/2017 | BKBWCVHYIG | Teva to use all available cash flow to cut debt until end of 2020
|
| 12/14/2017 | BKCVEMIG | Moody’s reviews Teva Pharmaceutical
|
| 12/14/2017 | CV | Market Commentary: Morning Commentary: Bristow makes gains on market debut, Teva active
|
| 11/27/2017 | CV | Market Commentary: Square tumbles after record high, health care companies active in post-holiday lull
|
| 11/13/2017 | CV | Market Commentary: Rambus, Quotient announce new deals, Square Inc. jumps, recent issues in demand
|
| 11/13/2017 | CV | Market Commentary: Morning Commentary: Square Inc. dominates early trades, Micron continues upwards climb
|
| 11/6/2017 | BKCVEMIG | Fitch downgrades Teva to BB
|
| 11/3/2017 | BKCVEMIG | S&P revises Teva to negative
|
| 10/5/2017 | CV | Market Commentary: Convertibles buyers step in to select names; supply remains tight; Navistar 4.5s gain
|
| 10/4/2017 | CV | Market Commentary: Convertibles primary market quiet again; Tesla convertibles expand in active trade; Teva lower
|
| 9/20/2017 | BKCVEMIG | S&P downgrades Teva
|
| 9/19/2017 | CV | Market Commentary: Sibanye brings new issue; Marriott Vacations, Maxwell add to calendar; Meritor on tap
|
| 9/19/2017 | CV | Market Commentary: Morning Commentary: Sibanye Gold bringing new issue; Meritor in the works; Teva trades again
|
| 9/13/2017 | CV | Market Commentary: Workday prices in the middle of talk, trades above par; Wayfair’s issue adds to gains
|
| 9/12/2017 | CV | Market Commentary: Wayfair’s new 0.375% convertibles trade up in heavy volume; Workday on tap; Teva firm
|
| 9/11/2017 | CV | Market Commentary: Wayfair, Workday add convertibles to calendar; Teva improves as new CEO named; Tesla up
|
| 9/11/2017 | CV | Market Commentary: Morning Commentary: Wayfair adds to calendar; Teva improves as new CEO named
|
| 8/22/2017 | CV | Market Commentary: II-VI plans new Rule 144A deal; Jazz edges above issue price; Red Hat busy; Teva assets eyed
|
| 8/4/2017 | CV | Market Commentary: Electronics for Imaging bonds drop on accounting troubles; Teva convertibles falter
|
| 8/4/2017 | BKCVIG | Fitch downgrades Teva to BBB-
|
| 8/4/2017 | BKCVEMIG | Moody's downgrades Teva
|
| 7/27/2017 | CV | Market Commentary: U.S. convertibles mixed as earnings in focus; recently priced Teladoc adds dollar neutral
|
| 7/13/2017 | CV | Market Commentary: Teva mandatories gain with stock on CEO chatter; Cobalt, Weatherford convertibles firm
|
| 7/13/2017 | CV | Market Commentary: Morning Commentary: Teva mandatories gain with stock on CEO chatter; Great Plains also firms
|
| 2/3/2017 | BKCVEMIG | S&P: Teva Pharmaceutical outlook to negative
|
| 1/31/2017 | CV | Market Commentary: Greenbrier deal set to price; Teva convertibles in decline as patents nixed; Rayonier lower
|
| 1/31/2017 | CV | Market Commentary: Morning Commentary: Greenbrier deal set to price; Teva convertibles in decline as patents nixed
|
| 10/13/2016 | CV | Market Commentary: Teva convertibles rise on swap; Fluidigm, Illumina pressured; Tesla bounces; DISH heavy
|
| 8/2/2016 | BKCVEMIG | Moody’s downgrades Teva to Baa2
|
| 7/22/2016 | BKCVEMIG | Fitch rates Teva bonds BBB
|
| 7/20/2016 | BKCVEMIG | Fitch downgrades Teva, rates bond BBB
|
| 7/18/2016 | BKCVEMIG | S&P rates Teva notes BBB
|
| 7/18/2016 | BKCVEMIG | Moody’s rates Teva notes Baa2
|
| 7/13/2016 | BKCVEMIG | S&P downgrades Teva
|
| 5/9/2016 | CV | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
| 5/9/2016 | CV | Market Commentary: Morning Commentary: Teva up a little in line with shares after posting decent earnings
|
| 5/6/2016 | CV | Market Commentary: Teva bonds improve on lower shares; Allergan mandatory drops; Chesapeake extends gains
|
| 5/6/2016 | CV | Market Commentary: Morning Commentary: Teva bonds move higher in active trade; Endo International weighs on drug sector
|
| 3/3/2016 | CV | Market Commentary: Herbalife lower on overstated member metric; Ctrip.com mixed on swap; Ciena drops
|
| 3/3/2016 | CV | Market Commentary: Morning Commentary: Herbalife lower on overstated new member metric; market remains better-bid
|
| 1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
| 1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
| 1/4/2016 | CV | Teva greenshoe ups 7% mandatory convertible preferreds to $3.7 billion
|
| 12/8/2015 | CV | Market Commentary: Convertibles weak as oil roils markets; Chesapeake down again; Harmonic looks cheap
|
| 12/3/2015 | CV | Market Commentary: Teva contracts on swap; new Inphi adds 0.5 point; Pandora, Vitamin Shoppe deals look cheap
|
| 12/3/2015 | CV | Market Commentary: Morning Commentary: New Teva lags; Inphi trades better; Pandora, Vitamin Shoppe deals look cheap
|
| 12/3/2015 | CV | New Issue: Teva prices $3.38 billion mandatory convertible preferreds to yield 7%, up 20%
|
| 12/2/2015 | CV | Market Commentary: Upsized Nuance edges up in trade; planned Inphi looks cheap; Teva on tap; Pandora launches
|
| 12/1/2015 | CV | Market Commentary: Planned Nuance convertibles slightly cheap; Teva deal timing accelerated; Inphi on tap
|
| 12/1/2015 | CV | Teva accelerates pricing of $3.38 billion mandatory convertible preferreds to Wednesday
|
| 11/30/2015 | CV | Market Commentary: Teva Pharmaceutical, Nuance launch large deals; existing Teva quiet; market eyes month-end
|
| 11/30/2015 | CV | Market Commentary: Morning Commentary: Planned Teva Pharmaceutical deal looks ‘cheap’; existing Teva quiet
|
| 11/30/2015 | CV | Teva Pharmaceutical plans $3.38 billion mandatory convertible to yield 6.75%-7.25%, up 17.5%-22.5%
|
| 11/25/2015 | BKCVEMIG | S&P rates Teva loan BBB+
|
| 11/5/2015 | CV | Israel’s Teva shareholders OK mandatory convertible preferred issue
|
| 7/28/2015 | CV | Market Commentary: Teva debt active; Micron, Intel firm on new chip; Whiting bonds rebound ahead of earnings
|
| 7/28/2015 | BKCVEMIG | S&P lowers Teva Pharmaceutical
|
| 7/28/2015 | CV | Market Commentary: Morning Commentary: Teva debt remains active; Whiting bonds rebound; Alpha issue set to mature
|
| 7/27/2015 | CV | Market Commentary: Teva convertibles soar on Allergan bid; Micron, Intel to hold press event; bonds higher
|
| 7/27/2015 | BKCVEMIG | Moody’s cuts Teva Pharmaceutical to Baa1
|
| 7/27/2015 | CV | Market Commentary: Morning Commentary: Teva convertibles rise on Allergan bid; trader expects IGI to remain firm
|
| 7/2/2015 | CV | Market Commentary: Convertibles quiet heading into holiday weekend; Teslas improve on strong deliveries
|
| 4/22/2015 | BKCVEMIG | Fitch: Teva on watch after merger news
|
| 4/22/2015 | BKCVEMIG | S&P: Teva on watch after Mylan deal announced
|
| 4/21/2015 | CV | Market Commentary: Mylan moves up in line on Teva bid; Lam Research jumps outright; Iconix continues to trade
|
| 4/21/2015 | BKCVEMIG | Moody's changes Teva outlook to negative
|
| 4/21/2015 | CV | Market Commentary: Morning Commentary: Mylan, Teva move up in line on merger deal news; Intel slips
|
| 4/16/2015 | CV | Market Commentary: SanDisk lower outright, edges up on swap; Teva below parity; planned Pernix looks cheap
|
| 4/9/2015 | CV | Market Commentary: Qihoo, other Asian internet names up again in active trade; Isis improves; Teva at parity
|
| 4/8/2015 | CV | Market Commentary: Qihoo bonds rise outright, on swap with higher Asian stocks; Mylan trades up outright
|
| 4/7/2015 | CV | Market Commentary: Convertibles firmer; Ctrip, Twitter improve on swap; SanDisk bonds active; Greenbrier eyed
|
| 3/31/2015 | BKCVEMIG | Moody's: Teva unchanged
|
| 3/30/2015 | CV | Market Commentary: Horizon Pharma jumps outright, adds on hedge; health-care bid remains strong; Intel active
|
| 3/30/2015 | CV | Market Commentary: Morning Commentary: Horizon Pharma jumps outright; health care bid remains strong; Intel active
|
| 3/24/2015 | BKCVEMIG | Moody's rates Teva notes A3
|
| 3/24/2015 | BKCVEMIG | S&P rates Teva notes A-
|
| 3/24/2015 | BKCVEMIG | Fitch assigns BBB+ to Teva bond
|
| 2/19/2015 | BKCVEMIG | Moody’s revises Teva to stable
|
| 1/21/2014 | CV | Market Commentary: NQ Mobile, Teva Pharmaceutical better on swap; Yandex in trade; YRC Worldwide in focus
|
| 12/11/2013 | BKCVEM | Fitch downgrades Teva
|
| 6/13/2013 | BKCVEM | Moody's: Teva view to negative
|
| 12/13/2012 | BKCVEM | Fitch rates Teva notes A-
|
| 12/13/2012 | CVEM | Moody's rates Teva notes A3
|
| 12/13/2012 | CVEM | S&P rates Teva notes A-
|
| 12/3/2012 | CV | Market Commentary: Teva trades after disappointing outlook; Volcano's planned $350 million convertible on tap
|
| 4/3/2012 | CVEMIG | S&P rates Teva notes A-
|
| 4/2/2012 | CVEMIG | Moody's rates Teva notes A3
|
| 3/29/2012 | CVEMIG | S&P rates Teva notes A-
|
| 2/15/2012 | CV | Market Commentary: Teva trades in line after earnings; NetApp heavy ahead of earnings; Central European gains
|
| 12/21/2011 | CVEMIG | Teva to end 2011 with $14.5 billion of debt, expects decrease in 2012
|
| 12/21/2011 | CVEMIG | Moody's: Teva unchanged
|
| 12/9/2011 | CVEMIG | Teva files automatic shelf registration for ADS, debt, units, warrants
|
| 12/6/2011 | BKCVEMIG | Teva has 'robust' rating, 'significant' cash flow for deleveraging
|
| 12/5/2011 | CV | Market Commentary: Convertibles quiet as equities react to European debt news; BorgWarner adds; AMR slips
|
| 11/7/2011 | CV | Market Commentary: Jefferies adds after unwinding euro debt; Amgen unmoved on share buyback, debt deal
|
| 11/7/2011 | CVEMIG | S&P assigns Teva notes A-
|
| 10/14/2011 | CV | Cephalon's 2.5%, 2% notes convertible into cash following Teva merger
|
| 8/22/2011 | CV | Cephalon announces expected make-whole conversion amounts for notes
|
| 8/9/2011 | CV | Teva Pharmaceutical unit's 0.25% debentures convertible until Nov. 11
|
| 8/2/2011 | CVEMIG | Moody's: Teva unchanged
|
| 5/31/2011 | CV | Market Commentary: Forestar to price $100 million deal; Newmont steady to down; Host little moved on partial call
|
| 5/31/2011 | CVLM | Teva will no longer redeem series A and B convertibles on June 21
|
| 5/23/2011 | CVLM | Teva to redeem 0.25%, 0.5% notes; holders may convert until June 17
|
| 5/11/2011 | CV | Teva Pharmaceutical unit's 0.25% debentures convertible until Aug. 12
|
| 5/3/2011 | BKCACVHY | Moody's confirms Valeant
|
| 5/2/2011 | CVEMIG | S&P affirms Teva
|
| 5/2/2011 | CVEMIG | Moody's affirms Teva
|
| 5/2/2011 | CVEMIG | Teva plans to use cash, bonds to acquire Cephalon for $6.8 billion
|
| 5/2/2011 | CV | Market Commentary: Cephalon adds outright, flat on hedge after Teva bid; Teva adds too; International Coal up
|
| 3/16/2011 | CVEMIG | S&P rates Teva notes A-
|
| 3/16/2011 | CVEMIG | Moody's rates Teva notes A3
|
| 2/4/2011 | CV | Outright convertible players add 1.9% for January, Citigroup says
|
| 2/1/2011 | CV | Teva Pharma's 0.25%, 0.5% debentures convertible until May 13
|
| 1/24/2011 | CV | Market Commentary: Salesforce.com under pressure; RadioShack lower; Molycorp plans mandatory; Nielsen on tap
|
| 1/13/2011 | CV | Market Commentary: Dendreon to price $500 million convertibles; Allergan active amid possible short covering
|
| 1/12/2011 | CV | Market Commentary: Hedged holders lose on Teva call; Nielsen mandatory to price Jan. 24 week; GM mandatory up
|
| 1/12/2011 | CV | Teva cuts conversion price of 1.75% convertibles due 2026
|
| 1/11/2011 | CVLM | Teva to redeem $813 million 1.75% convertible debentures due 2026
|
| 11/10/2010 | CV | Teva cuts conversion prices on 0.5%, 0.25% convertibles due 2024
|
| 11/9/2010 | CV | Teva 0.25%, 0.5% notes convertible into ADRs from Nov. 11 to Feb. 14
|
| 8/10/2010 | CV | Teva says 0.5%, 0.25% notes convertible till Nov. 11, adjusts conversion price on two other series
|
| 6/22/2010 | CV | Market Commentary: Teva series Ds active in trade; Transocean ends lower; Biovail, Lincare better; PPL adds
|
| 6/2/2010 | CV | Teva Pharmaceutical holders may convert 0.5%, 0.25% notes 'til Aug. 12
|
| 6/1/2010 | CV | Market Commentary: Transocean extends fall; Superior Energy off; Western Refining under pressure; Teva slips
|
| 3/19/2010 | CVEMIG | S&P ups Teva Pharmaceutical
|
| 3/18/2010 | BKBWCV | Teva to use cash, lines of credit to fund Ratiopharm acquisition
|
| 3/18/2010 | CVEMIG | Moody's affirms Teva Pharmaceuticals
|
| 2/18/2010 | CV | Teva Pharmaceutical holders may convert 0.5%, 0.25% notes up to May 13
|
| 1/13/2010 | CVEMIG | Moody's lifts Teva
|
| 11/11/2009 | CV | Teva Pharmaceutical's 0.5% debentures now convertible up to Feb. 16
|
| 11/3/2009 | CV | Teva extends convertibility of 0.5% notes, 0.25% notes until Feb. 16
|
| 10/14/2009 | CVEMIG | Moody's upgrades Teva
|
| 8/5/2009 | CV | Teva adjusts conversion prices of 0.25%, 1.75% convertibles, announces convertibility of 0.5% bonds
|
| 8/3/2009 | CV | Teva extends convertibility of 0.25% convertibles to Nov. 11
|
| 7/30/2009 | CV | Teva extends convertibility of 0.25% convertibles to Tuesday
|
| 7/27/2009 | CV | Teva extends convertibility of 0.25% convertibles to Thursday
|
| 7/23/2009 | CV | Teva extends convertibility of 0.25% convertibles to Tuesday
|
| 7/22/2009 | CV | Teva extends convertibility of 0.25% convertibles to Monday
|
| 7/21/2009 | CV | Teva extends convertibility of 0.25% convertibles to Friday
|
| 7/20/2009 | CV | Teva extends convertibility of 0.25% convertibles to Thursday
|
| 7/16/2009 | CV | Teva extends convertibility of 0.25% convertibles to Tuesday
|
| 7/15/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Monday
|
| 7/13/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Thursday
|
| 7/9/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Tuesday
|
| 7/8/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Monday
|
| 7/2/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Tuesday
|
| 6/29/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Thursday
|
| 6/24/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Tuesday
|
| 6/23/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Friday
|
| 6/22/2009 | CV | Teva issues notices of convertibility for 0.5%, 0.25% convertibles
|
| 6/18/2009 | CV | Market Commentary: Whiting Petroleum slips below par on debut; Watson up; newly priced issues in focus
|
| 6/18/2009 | CV | Teva series A, series B debentures convertible through June 23
|
| 5/18/2009 | CVEM | Moody's lifts Teva Pharmaceuticals outlook to positive
|
| 3/30/2009 | CV | Teva A convertibles best for high delta; Cs offer more balance, Barclays analysts say
|
| 1/6/2009 | CVEMIG | Moody's affirms Teva, ups Barr loan
|
| 12/4/2008 | CVEMIG | Teva files automatic shelf registration
|
| 11/18/2008 | CV | Market Commentary: Financials mostly weaker; Medtronic, Teva mixed; Digital River strong despite steep slide in shares
|
| 8/28/2008 | CV | Market Commentary: Teva edges higher amid outright interest; Peabody eases; Fleetwood aims to extend 5% convertibles
|
| 7/18/2008 | BKCVEMIG | Moody's may upgrade Barr, affirms Teva
|
| 7/18/2008 | CV | Market Commentary: Bank of America, Washington Mutual, Wachovia gain; Teva climbs; Sino-Forest, Trina quiet on debuts
|
| 7/8/2008 | CV | Market Commentary: EMC trades mixed, Teva up outright; Lehman mostly higher; Transocean adds despite lower oil prices
|
| 3/17/2008 | CV | S&P boosts Teva
|
| 3/13/2008 | CV | Lehman analysts: Teva tranche D convertibles now look better to buy
|
| 2/29/2008 | CV | Market Commentary: EMC, Mylan, Sprint, National Retail convertibles all lower; Teva flat; equities sink
|
| 2/28/2008 | CV | Market Commentary: Convertibles mostly lower; National Retail edges below par; Thornburg, Nextel drop
|
| 2/27/2008 | CV | Lehman analysts: Sell the A, C Teva convertibles to buy the Teva Bs
|
| 2/27/2008 | CV | Market Commentary: Convertibles trade mixed; Teva, Fannie Mae active; National Retail prices upsized notes
|
| 1/31/2008 | CV | S&P could lift Teva
|
| 10/16/2007 | CV | Teva calls $36 million of 0.375% convertible debentures due 2022
|
| 10/15/2007 | CVSP | New Issue: Svensk prices $73.7 million 10% exchange notes linked to Teva Pharmaceuticals
|
| 2/14/2007 | CV | Market Commentary: Genzyme, Transocean climb on results; Teva gains further on outlook; Archer Daniels Midland plans deal
|
| 11/7/2006 | BTCVEM | Teva board OKs repurchase of up to $600 million convertibles, shares
|
| 8/8/2006 | CV | Market Commentary: McData gains with offer; Teva rides earnings boost; Scottish Re firms as put stays; Charter slips on loss
|
| 7/26/2006 | CV | New Issue: Barclays sells $3 million 9% reverse convertibles linked to Teva Pharmaceutical
|
| 7/17/2006 | CV | Market Commentary: Nabors falls with oil prices; Electronics for Imaging brightens with upgrade; Lucent still weak on forecasts
|
| 7/14/2006 | CV | Market Commentary: Ford slides as story sputters; GM weaker; deCODE Genetics widens; Teva steady despite loss to Forest
|
| 7/10/2006 | CV | Barclays plans issue of 9% exchangeables linked to Teva Pharmaceutical
|
| 6/21/2006 | CV | Market Commentary: Teva sinks outright, holds up dollar neutral; Group 1 re-offered; $2 billion new deals seen pricing Thursday
|
| 5/25/2006 | CV | Market Commentary: Encysive gains outright on FDA submission; Omnicare, XM Satellite better on hedge amid stock declines
|
| 5/10/2006 | CV | Market Commentary: SanDisk, Broadwing climb on debuts; Amkor, JDS Uniphase, Manor Care plan deals; Teva steady on loss
|
| 5/5/2006 | CV | Market Commentary: Safenet gains on earnings, stock buyback; Scottish Re widens after poor quarter; Finisar flat after rally
|
| 5/1/2006 | CV | Market Commentary: Level 3 gains on $1.2 billion acquisition; Teva gets court boost; Human Genome tightens on drug trials
|
| 3/6/2006 | CV | Market Commentary: Coherent, Albany International launch new deals; Teva, General Motors gain on positive news
|
| 2/24/2006 | BTCV | Teva over-allotment option partially exercised, raising convertibles to $1.3925 billion
|
| 2/2/2006 | CV | Market Commentary: ImClone steady despite lack of Bristol-Myers interest; Teva under pressure; Omnicare edges lower
|
| 1/27/2006 | BTCVEM | Moody's rates Teva Pharmaceutical notes, convertibles Baa2
|
| 1/27/2006 | CV | Market Commentary: Deals from Teva, AAR draw attention to new issues; Nektar in play on product rumors; GM up
|
| 1/27/2006 | BTCVEM | New Issue: Teva prices $1.25 billion convertibles at 1.75%, up 25%, 0.25%, up 15%
|
| 1/26/2006 | BTCVEM | S&P assigns Teva Pharmaceutical notes BBB
|
| 1/26/2006 | CV | Market Commentary: New issues mixed, NRG trades up, UAG flat; Juniper drops; DRS launches $300 million of convertibles
|
| 1/25/2006 | CV | Market Commentary: Cracker Barrel, Calpine gain; Charter edges lower; Teva, AAR launch convertible deals
|
| 1/25/2006 | CV | Teva Pharmaceuticals to price $1.25 billion 20-year convertibles in two tranches
|
| 1/4/2006 | CV | Market Commentary: Convertible market sees broad-based gains, GM, Ford lift; airlines better, Calpine adds points
|
| 1/3/2006 | BTCV | Teva does not exercise fundamental change option for IVAX 1.5% convertibles due 2025
|
| 12/20/2005 | BTCVEM | Teva files shelf, may use sales to finance IVAX acquisition
|
| 12/9/2005 | CV | Market Commentary: Cephalon, Teva gain on patent settlement; eyes turn toward Omnicare; Alltel mostly quiet
|
| 12/8/2005 | CV | Market Commentary: New SafeNet convertibles gain with shares; technology and biotech firmer; LabCorp gains
|
| 12/6/2005 | BTCV | Teva does not expect to choose fundamental change option for IVAX 1.5% convertibles due 2025
|
| 11/28/2005 | CV | Market Commentary: Airline, retail convertibles attract bids; Platinum Underwriters launches $150 million preferreds
|
| 11/11/2005 | CV | S&P affirms Teva Pharmaceutical
|
| 11/3/2005 | CV | Market Commentary: Chesapeake, Qwest trade higher; Abgenix, Amgen rise, but ImClone lower; SFBC plunges
|
| 11/2/2005 | BTCVEM | Moody's gives Teva Baa2 issuer rating
|
| 10/25/2005 | CV | Market Commentary: Sovereign slides, Schlumberger, Sepracor lift; Essex reoffered at 98; Flextronics drops after close
|
| 8/3/2005 | CV | Market Commentary: Human Genome to price $230 million of convertibles; Reebok paper jumps on buyout news
|
| 8/1/2005 | CV | Market Commentary: CommScope jumps, but Isolagen tumbles amid slightly weaker convertibles market
|
| 7/25/2005 | BTCVEM | S&P puts Teva on negative watch
|
| 7/25/2005 | CV | Market Commentary: CSK on tap; L-3, Barnes, Manor Care, FTI, Conseco later in week; Ivax in quandary on Teva merger
|
| 5/25/2005 | CV | S&P ups Teva view to stable
|
| 4/15/2005 | CV | Market Commentary: GM, Ford selling accelerates; El Paso, Calpine, NRG plunge; Ivax, Teva lose; Lucent, Tyco unwound
|
| 2/28/2005 | CV | Market Commentary: Elan hurt, Biogen stable; Teva up, Schering slips; King trips; Yellow skids; Manpower lower; Saks off
|
| 2/22/2005 | CV | Market Commentary: Level 3 converts rise on private deal; UniSource, Allied Waste deals emerge; Par, Ivax, Teva up
|
| 12/22/2004 | CV | New Issue: Lehman prices $5 million 0% up 13.85% notes linked to Teva
|
| 12/21/2004 | CV | Teva ups buyback program to $600 million
|
| 10/15/2004 | CV | Top volatility plays: BankUnited, Schlumberger, Teva, HCC Insurance, Quanex, Merrill says
|
| 10/11/2004 | CV | Market Commentary: Northwest, Delta lead lower on fuel prices, pilot contract concerns; drug paper higher
|
| 9/3/2004 | CV | Teva board authorizes buybacks of $300 million of shares, convertibles
|
| 8/30/2004 | CV | Market Commentary: LNR convertible leveled by $1.9 billion cash takeover; United Rentals falls on SEC inquiry
|
| 8/20/2004 | CV | Teva Pharmaceutical says almost all $349 million of 0.75% debentures converted
|
| 8/17/2004 | CV | S&P: Teva unaffected
|
| 7/30/2004 | CV | Teva calls all $349 million of 0.75% convertibles
|
| 5/20/2004 | CV | Market Commentary: Airline paper cheapens further, despite rise in stocks; Guilford shelf uplifts holders of rich bonds
|
| 2/6/2004 | CV | Teva greenshoe partially exercised, raising convertibles to $1.094 billion
|
| 2/3/2004 | CV | Market Commentary: First Data's call catches some off guard, Delta reoffered at 97, descends to 95.75 bid; Tyco up
|
| 1/29/2004 | CV | Market Commentary: Wyeth, Sallie Mae, Lockheed floaters see demand; hedgies hurt by premium contractions
|
| 1/23/2004 | CV | Lehman analysts add new Teva 0.5% convert to recommended portfolio, overweight on stock
|
| 1/23/2004 | CV | S&P rates new Teva convertibles BBB
|
| 1/23/2004 | CV | Market Commentary: Comtech dips on telecom slump; other new issues still on the rise; buyer seen for Adelphia converts
|
| 1/22/2004 | CV | Market Commentary: Komag delayed a day on Maxtor earnings, still bid up 2.5 points; Kodak's paper snapped up on new plan
|
| 1/22/2004 | CV | New Issue: Teva sells $1 billion convertibles; Tranche A at 0.5%, up 29%; Tranche B at 0.25%, up 20%
|
| 1/21/2004 | CV | Teva $1 billion overnight two-tranche convert talked at 0.25-0.5%, up 29-35% and 0.0-0.25%, up 20-26%
|
| 1/21/2004 | CV | Market Commentary: Deals totaling $1.9 billion at bat; Citi/News, Teva see only offers; Komag tightened, still bid higher
|
| 10/31/2003 | CV | S&P cuts Teva outlook
|
| 10/15/2003 | CV | S&P ups Teva to BBB
|
| 10/15/2003 | CV | Teva says almost all 1.5% convertibles exchanged for stock
|
| 10/2/2003 | CV | Market Commentary: Providian gains sharply amidst big volume on talk about Wells Fargo takeover; buyers aplenty
|
| 9/29/2003 | CV | S&P puts Teva on positive watch
|
| 9/25/2003 | CV | Market Commentary: Pharma Resources gains to 104 despite complaint; Bristol-Myers jumbo seen offered at par in gray
|
| 9/25/2003 | CV | Teva calls 1.5% convertibles
|
| 8/28/2003 | CV | Market Commentary: Miscellaneous scraps of convertible paper trading; action to heat up next week
|
| 6/24/2003 | CV | Moody's rates Halliburton convertible Baa2
|
| 6/23/2003 | CV | Market Commentary: Market cheapening poses double-edged sword as new paper suffers; 4 deals emerge
|
| 5/5/2003 | CV | Market Commentary: Tech names higher, partly on Lucent/Juniper agreement; LIN, Edwards pricing before Tuesday open
|
| 4/30/2003 | CV | Market Commentary: Tyco convertibles drop to 97 on accounting charge news only to end higher at 102
|
| 4/3/2003 | CV | Market Commentary: Refinancing hopes, quest for delta provide buying catalyst; HealthSouth firmer on rescue hopes
|
| 3/5/2003 | CV | Market Commentary: Watson trades up out of gate, Provident plunges, call scare ripples throughout market
|
| 3/4/2003 | CV | Deutsche says Teva 0.375% convertibles best for outrights, 1.5% least attractive
|
| 1/14/2003 | CV | Market Commentary: Some expect credit spread rally to begin leveling off; Oneok mandatory guidance emerges
|
| 11/27/2002 | CV | Market Commentary: Opportunists take profits in Skyworks, new issues gain
|
| 11/19/2002 | CV | Market Commentary: New issue terms, credits not so fantastic, but illustrate appetite
|
| 11/18/2002 | CV | Market Commentary: Trickle of new issues providing hope for eager buyers
|
| 11/15/2002 | CV | Market Commentary: American Tower gains sharply on hopes of exchange offer; 3M, Teva continue northward
|
| 11/14/2002 | CV | Market Commentary: Buyers emerge from sidelines to bid up high delta, gamma issues
|
| 11/13/2002 | CV | Market Commentary: Teva deal gets warm welcome in an otherwise tepid market
|
| 11/13/2002 | CV | New Issue: Teva $375 million convertibles yield 0.375%, up 18%
|
| 11/13/2002 | CV | S&P rates Teva at BBB-
|
| 11/12/2002 | CV | Market Commentary: New deals provide stimulation late, after very quiet session
|
| 11/12/2002 | CV | Teva launches quick-sale $375 million converts at 0.375-0.625%, up 18-22%
|
| 4/10/2002 | CV | Deutsche analysts say credit work provides insight for generic drug picks
|
| 1/7/2002 | CV | Market Commentary: Convertibles sink on profit taking as stocks retreat
|
